Literature DB >> 12008087

Marrow stroma in MDS: culprit or bystander?

H Joachim Deeg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12008087     DOI： 10.1016/s0145-2126(02)00015-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  10 in total

1.  Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide.

Authors:  Ruben A Ferrer; Manja Wobus; Catrin List; Rebekka Wehner; Claudia Schönefeldt; Barbara Brocard; Brigitte Mohr; Martina Rauner; Marc Schmitz; Maik Stiehler; Gerhard Ehninger; Lorenz C Hofbauer; Martin Bornhäuser; Uwe Platzbecker
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 2.  Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

Authors:  Xiang Li; H Joachim Deeg
Journal:  Exp Hematol       Date:  2013-10-11       Impact factor: 3.084

3.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

Review 4.  Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system.

Authors:  Marc H G P Raaijmakers
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

5.  Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.

Authors:  Diana Campioni; Paola Secchiero; Federica Corallini; Elisabetta Melloni; Silvano Capitani; Francesco Lanza; Giorgio Zauli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS.

Authors:  A Mario Marcondes; Aravind Ramakrishnan; H Joachim Deeg
Journal:  Curr Cancer Ther Rev       Date:  2009-11-01

Review 7.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

8.  Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors:  Tony Navas; Li Zhou; Myka Estes; Edwin Haghnazari; Aaron N Nguyen; Yongkai Mo; Perry Pahanish; Mani Mohindru; Tim Cao; Linda S Higgins; Leonidas C Platanias; Alan List; Amit Verma; T Bhagat; S Gajavelli; S Kambhampati
Journal:  Leuk Lymphoma       Date:  2008-10

Review 9.  A novel role for the marrow microenvironment in initiating and sustaining hematopoietic disease.

Authors:  Aravind Ramakrishnan; H Joachim Deeg
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

Review 10.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.